BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26847798)

  • 1. A novel LC-MS/MS assay for heparan sulfate screening in the cerebrospinal fluid of mucopolysaccharidosis IIIA patients.
    Naimy H; Powell KD; Moriarity JR; Wu J; McCauley TG; Haslett PA; Barbier AJ; Qiu Y
    Bioanalysis; 2016 Feb; 8(4):285-95. PubMed ID: 26847798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust LC-MS/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA.
    Makower Å; Arnelöf E; Andersson T; Edlund PO; Gustavsson S; Janson J; Gelius SS; Tjernberg A
    Bioanalysis; 2019 Aug; 11(15):1389-1403. PubMed ID: 31490106
    [No Abstract]   [Full Text] [Related]  

  • 3. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.
    Zhang H; Wood T; Young SP; Millington DS
    Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry.
    Tomatsu S; Montaño AM; Oguma T; Dung VC; Oikawa H; Gutiérrez ML; Yamaguchi S; Suzuki Y; Fukushi M; Barrera LA; Kida K; Kubota M; Orii T
    Mol Genet Metab; 2010 Feb; 99(2):124-31. PubMed ID: 19932038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic Disaccharide Standards Enable Quantitative Analysis of Stored Heparan Sulfate in MPS IIIA Murine Brain Regions.
    He QQ; Trim PJ; Lau AA; King BM; Hopwood JJ; Hemsley KM; Snel MF; Ferro V
    ACS Chem Neurosci; 2019 Aug; 10(8):3847-3858. PubMed ID: 31264853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel heparan sulfate assay by using automated high-throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses.
    Shimada T; Kelly J; LaMarr WA; van Vlies N; Yasuda E; Mason RW; Mackenzie W; Kubaski F; Giugliani R; Chinen Y; Yamaguchi S; Suzuki Y; Orii KE; Fukao T; Orii T; Tomatsu S
    Mol Genet Metab; 2014; 113(1-2):92-9. PubMed ID: 25092413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple method for early age phenotype confirmation using toe tissue from a mouse model of MPS IIIA.
    Trim PJ; Lau AA; Hopwood JJ; Snel MF
    Rapid Commun Mass Spectrom; 2014 Apr; 28(8):933-8. PubMed ID: 24623698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel LC-MS/MS assay to quantify dermatan sulfate in cerebrospinal fluid as a biomarker for mucopolysaccharidosis II.
    Pan P; Chen M; Zhang Z; Corte AD; Souza C; Giugliani R; Pan L; Qiu Y; Amaravadi L; Wu J
    Bioanalysis; 2018 Jun; 10(11):825-838. PubMed ID: 29863901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
    de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
    Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Butanolysis derivatization: improved sensitivity in LC-MS/MS quantitation of heparan sulfate in urine from mucopolysaccharidosis patients.
    Trim PJ; Hopwood JJ; Snel MF
    Anal Chem; 2015 Sep; 87(18):9243-50. PubMed ID: 26301744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multiplex Assay for the Diagnosis of Mucopolysaccharidoses and Mucolipidoses.
    Langereis EJ; Wagemans T; Kulik W; Lefeber DJ; van Lenthe H; Oussoren E; van der Ploeg AT; Ruijter GJ; Wevers RA; Wijburg FA; van Vlies N
    PLoS One; 2015; 10(9):e0138622. PubMed ID: 26406883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI.
    Auray-Blais C; Bhérer P; Gagnon R; Young SP; Zhang HH; An Y; Clarke JT; Millington DS
    Mol Genet Metab; 2011 Jan; 102(1):49-56. PubMed ID: 20934363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of an LC-MS/MS Method for the quantitation of heparan sulfate in human urine.
    Wang K; Li M; Xiao Y; Ma M; Hu W; Liang T; Lin ZJ
    Biomed Chromatogr; 2018 Oct; 32(10):e4294. PubMed ID: 29797526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA.
    Jones SA; Breen C; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Pan L; Qiu Y; Chung JK; Nair N; Haslett PAJ; Barbier AJ; Wijburg FA
    Mol Genet Metab; 2016 Jul; 118(3):198-205. PubMed ID: 27211612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy.
    Zhang H; Dickson PI; Stiles AR; Chen AH; Le SQ; McCaw P; Beasley J; Millington DS; Young SP
    Clin Chim Acta; 2020 Sep; 508():179-184. PubMed ID: 32442432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses.
    Chuang CK; Lin HY; Wang TJ; Tsai CC; Liu HL; Lin SP
    Orphanet J Rare Dis; 2014 Sep; 9():135. PubMed ID: 25178307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of heparan sulfate and dermatan sulfate in mucopolysaccharidosis type II mouse tissues pre- and post-enzyme-replacement therapy determined by UPLC-MS/MS.
    Menkovic I; Lavoie P; Boutin M; Auray-Blais C
    Bioanalysis; 2019 Apr; 11(8):727-740. PubMed ID: 30994022
    [No Abstract]   [Full Text] [Related]  

  • 19. Normalization of glycosaminoglycan-derived disaccharides detected by tandem mass spectrometry assay for the diagnosis of mucopolysaccharidosis.
    Lin HY; Lo YT; Wang TJ; Huang SF; Tu RY; Chen TL; Lin SP; Chuang CK
    Sci Rep; 2019 Jul; 9(1):10755. PubMed ID: 31341247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry.
    Kubaski F; Mason RW; Nakatomi A; Shintaku H; Xie L; van Vlies NN; Church H; Giugliani R; Kobayashi H; Yamaguchi S; Suzuki Y; Orii T; Fukao T; Montaño AM; Tomatsu S
    J Inherit Metab Dis; 2017 Jan; 40(1):151-158. PubMed ID: 27718145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.